Topical finasteride 0.25%: 75% of the hair effect, 34.5% of the systemic DHT drop

Topical finasteride exists. It cuts your scalp DHT by ~64-70% — close to oral — but only drops your blood DHT by ~34.5%. Less systemic exposure, fewer reported side effects, similar hair retention.

The reason your derm doesn't prescribe it: there's no FDA-approved branded version in the US.

Outside the US, it's been Phase III validated since 2022.

Up front: this article is partially against our routed catalog.

We don't currently route topical finasteride 0.25% solution as a stocked product. We route oral finasteride generics — Finpecia, Curlzfin, F-Pecia — and topical minoxidil. So pointing you toward topical means pointing some users toward Hims's compounded spray or a different importer instead of toward our catalog.

We still wrote this. For a real fraction of users — the ones who tried oral 1mg and felt something, or whose family history makes them refuse any systemic exposure — topical is the de-escalation lane that didn't exist before 2016.

The PFS reality, scaled to actual numbers.

Persistent post-finasteride syndrome is real. It's also rare, and the fear is roughly 10x bigger than the rate.

Healy 2022's review of FDA Adverse Event Reporting data on finasteride and similar drugs estimated persistent post-treatment sexual dysfunction at roughly 2-5% of reported users, with another 5-10% reporting transient symptoms during use that resolve on stopping. (1.4% vs 30% breakdown of where those numbers come from is here.)

So the realistic mental model:

• 75-85% of men on 1mg oral notice no sexual side effect.
• 5-10% notice something during use that resolves when they stop.
• 2-5% report symptoms persisting after they stop.

For the bottom 2-5%, oral finasteride is a wrong-direction drug — they should never have started, or they should stop and not restart. For the middle 5-10% — the transient group — topical 0.25% is the de-escalation. Same molecule, ~35% of the serum exposure, side effect profile in trials closer to placebo.

The de-escalation didn't exist before 2016. Now it does, and most US derms are still acting like it doesn't.

The Piraccini 2022 trial — what made it real.

Piraccini BM et al., JEADV 2022 (doi:10.1111/jdv.17738). Phase III randomized, double-blind, controlled trial. Topical finasteride 0.25% spray solution vs oral finasteride 1mg vs placebo, in men with androgenetic alopecia, 24 weeks.

The results that change the conversation:

• Hair count change. Topical and oral both significantly better than placebo. Statistically not different from each other on the primary efficacy endpoint.
• Investigator Global Assessment. Topical comparable to oral — graders couldn't reliably tell them apart on visual change.
• Serum DHT reduction at week 24. Topical -34.5% from baseline. Oral 1mg -55.6%. Placebo: no change.
• Side effect profile. Topical roughly placebo-equivalent. Oral showed the expected attributable signal.

So the headline math: topical gets you the hair effect with about half the blood-level DHT suppression of oral. It's not a worse drug — it's the same molecule routed through a different pharmacokinetic path.

Earlier dose-finding work (Caserini 2014, PMID 25074865; Caserini 2016, PMID 26636418) established that the 0.25% concentration produced scalp DHT reduction comparable to oral with markedly less serum penetration. Piraccini 2022 took it through Phase III to confirm clinical equivalence on hair outcomes.

A note on a common citation error: some articles call this "Caserini Phase III." It isn't. Caserini did the early dose-ranging and DHT pharmacokinetics. Piraccini 2022 is the Phase III pivotal. Worth getting right because the date (2022, not 2014) is the difference between "old data" and "modern".

Why the systemic DHT drops less.

Topical finasteride is absorbed locally into the scalp. Type II 5α-reductase is concentrated in the dermal papilla and outer root sheath of hair follicles — exactly where the topical solution sits. The drug saturates the local enzyme; that's why scalp DHT drops sharply.

Some drug leaks into systemic circulation through skin capillaries. But the effective serum concentration stays low — well below the steady-state plasma level of an oral 1mg tablet. Without that systemic concentration, full body-wide 5α-reductase suppression doesn't happen, which is why serum DHT drops ~35% instead of ~70%.

Topical finasteride is a thermostat that runs hot at the scalp and lukewarm everywhere else. Oral finasteride runs the same temperature in your scalp, your prostate, your liver, your testes, and your CNS. The hair endpoint cares about your scalp. The side-effect endpoint cares about everywhere else. Topical separates those.

Why your US derm won't prescribe it.

Most US dermatologists, asked about topical finasteride, will say "it's not FDA-approved, so I can't really comment."

Translation: there's no branded product, no manufacturer's rep, no insurance code, no compliant supply chain. The US prescription path requires either a compounding pharmacy (which makes the derm responsible for an unbranded formulation) or referral to a telehealth platform (which moves the risk off their license). Most just default to oral 1mg, which fits the prescription pathway cleanly.

That's a regulatory bottleneck, not a clinical one. Outside the US, topical finasteride is prescribed routinely — Italy, Germany, Portugal, parts of the EU and select non-US markets including South Korea and Saudi Arabia. The data isn't the question.

The question is who in the US distribution chain takes the regulatory liability for a product without an NDA. Currently, nobody — except compounding pharmacies under telehealth umbrellas (Hims, Roman), at telehealth markup.

The 3 ways to actually get topical finasteride.

1. US compounding pharmacy via telehealth. Hims sells topical finasteride spray standalone at $29/month (or $33/month bundled with ketoconazole and biotin) — custom-compounded by a US-licensed pharmacy under a Hims-affiliated provider's prescription. Roman sells topical finasteride spray at roughly $50/month. Keeps tends to bundle topical with minoxidil rather than offer a clean standalone. The molecule is real; the markup is the cost of the questionnaire-and-prescription layer.

2. Personal-import under the FDA personal-use policy. Under the FDA's Regulatory Procedures Manual (RPM) Chapter 9, Section 9-2 — operating under FDCA Section 801 — a 90-day supply for personal use of medications without an FDA-approved label can pass border review. Some Indian compounding-style pharmacies make 0.25% solutions, but it isn't a routine SKU at the major personal-import lanes the way oral 1mg is. Availability is intermittent.

3. DIY conversion. Crush a 1mg oral tablet, dissolve in 1mL of ethanol or in a minoxidil topical. The chemistry is fragile — finasteride solubility is finicky, the suspension settles, dose per spray is unreliable. None of the internet recipes have been validated for delivery consistency. Listed for completeness, not as a recommendation.

The 6-tier price reality.

Two honest reads of this table:

If you're already comfortable with oral 1mg, the routed lane is roughly 4-8x cheaper than even the cheapest US topical option, and the data on hair retention is stronger and longer.

If oral 1mg has given you a transient side effect or you're worried about even a 5-10% chance, the right answer might not be us. Hims's compounded spray at $29/mo is the most accessible topical lane in the US. The price difference vs our oral 1mg ($3.6-7.3/mo on Curlzfin or Finpecia, 90-pack) is the de-escalation premium — and it's worth paying if you're in the worried fraction.

Decision matrix: oral vs topical.

Pick topical over oral if:

• You have a family history of PFS-like reactions, or you're in the side-effect-cautious fraction worried about even a 5-10% chance.
• You started oral 1mg, had a transient libido drop or mood change, stopped, recovered — and want to try again with less systemic exposure.
• You're an athlete or your sex life is non-negotiable, and you refuse any systemic 5α-reductase blockade.
• Your goal is maximal scalp DHT suppression with minimal serum impact — the niche where topical's pharmacokinetics actually win.

Pick oral if:

• You're already on 1mg/day, side-effect free, hair stable. Don't fix what isn't broken.
• Cost matters. $3.6-7.3/mo (routed Curlzfin, Finpecia at 90-pack) vs $29-50/mo (compounded topical) is a real gap.
• Once-daily compliance matters. A pill is one habit. Topical spray twice daily on a dry scalp, with minutes-of-drying time, is harder to keep up. Adherence drops quickly.
• You're at NW4-6 with diffuse thinning and want maximum DHT inhibition. Oral 1mg or even dutasteride is a stronger lever for advanced patterns.

The user worth paying attention to is the one in the middle: NW2-3, mild to moderate, side-effect-cautious, willing to do twice-daily application, willing to pay 3-5x more per month for the systemic-exposure reduction. That's the user topical was actually designed for.

Action: where to actually start, by current state.

On 1mg oral, fully tolerating it, hair stable: stay on oral. Don't pre-empt a problem you don't have.

On 1mg oral, transient sexual side effects: step down first — try alternate-day dosing (1mg every other day, ~50% of a daily dose) or 0.5mg/day (split the tablet with a $5 cutter). Re-measure at 4 weeks. If the side effect persists, switch to topical 0.25% — Hims compounded spray ($29/mo standalone) if US-based and you accept the markup, or wait for personal-import availability if you're price-sensitive and time-flexible.

Never started, worried about side effects: start with topical 0.25% first. Twice daily, dry scalp. Reassess at month 12 (hair changes are slow on either route). If no measurable progress at month 12, then escalate to oral 1mg with the side-effect protocol from the 1.4% vs 30% piece.

Starting fresh, no specific side-effect worry: oral 1mg is cheaper, simpler, and has 25 years of post-marketing safety data. Topical has 3 years of Phase III data (good data, but less of it). For an unworried user, the depth of evidence behind oral plus the cost differential favors oral.

A note on bias.

We route oral finasteride orders. Be aware of that.

LiberaCure routes orders to licensed personal-import pharmacies. Finpecia (by Cipla), Curlzfin (by Canixa Life Sciences), and F-Pecia (by Cipla) are oral 1mg finasteride SKUs we ship most often. We don't currently route topical 0.25% solution as a stocked product. When a personal-import partner has it, we'll route it; right now they don't, in any consistent way.

So this article is partially against the catalog we actually carry. The right answer for some users isn't us — it's a US compounding pharmacy via Hims at $29/mo, accepting the markup as the price of the de-escalation. For users on oral 1mg with no side effects, our routed lane at $3.6-7.3/mo (Curlzfin or Finpecia 90-pack) is the cheaper and equally effective path. Both can be true.

Read this with that in mind. The protocol above is what I'd tell a friend deciding between systemic and topical, not what maximizes our reorder rate. If the right move for you is the topical lane and not us, that's the right move.

For reference on policy: LiberaCure reships once free if tracking shows lost in transit. Second reship also free. Crypto refund (BTC/ETH/USDT) on third failure. Email reply 24-48h ([email protected]). Lead time ~2 weeks from a licensed Indian pharmacy.

Sources:

• Piraccini BM et al. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. J Eur Acad Dermatol Venereol 2022;36(2):286-294. doi:10.1111/jdv.17738 (Phase III pivotal — topical 0.25% spray vs oral 1mg vs placebo, 24 weeks.)
• Caserini M et al. Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men with androgenetic alopecia. Int J Clin Pharmacol Ther 2014;52(10):842-849. PMID 25074865 (early pharmacokinetics).
• Caserini M et al. A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers. Int J Clin Pharmacol Ther 2016;54(1):19-27. PMID 26636418 (scalp/serum DHT comparison, dose-finding).
• Healy D et al. Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride, and isotretinoin. Int J Risk Saf Med 2022;33(1):65-76. doi:10.3233/JRS-210023 (PFS criteria; AERS-derived rates).
• Kaufman KD et al. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol 1998;39(4 Pt 1):578-589. (PROPECIA pivotal trials, oral 1mg sexual side effect baseline.)
• FDA Regulatory Procedures Manual (RPM) Chapter 9, Section 9-2: Coverage of Personal Importations (under FDCA Section 801) — 90-day personal-use supply provisions.
• Hims and Roman topical finasteride pricing, accessed May 2026.

Related:

• Hair loss comprehensive guide (pillar)
• Finasteride side effects: 1.4% vs 30% — both are right
• Finasteride 5-brand teardown (Cipla and friends)
• Dutasteride: when to escalate from finasteride

— LiberaCure editorial. We route generic medication through licensed personal-import pharmacies. We don't dispense, prescribe, or warehouse. Read more about why.